Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development

@article{Nierenberg2013MitochondrialMF,
  title={Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development},
  author={A. Nierenberg and C. Kansky and B. Brennan and R. Shelton and R. Perlis and D. Iosifescu},
  journal={Australian \& New Zealand Journal of Psychiatry},
  year={2013},
  volume={47},
  pages={26 - 42}
}
Objectives: Bipolar patients frequently relapse within 12 months of their previous mood episode, even in the context of adequate treatment, suggesting that better continuation and maintenance treatments are needed. Based on recent research of the pathophysiology of bipolar disorder, we review the evidence for mitochondrial dysregulation and selected mitochondrial modulators (MM) as potential treatments. Methods: We reviewed the literature about mitochondrial dysfunction and potential MMs worthy… Expand
Mitochondrial Agents for Bipolar Disorder
TLDR
The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder’s pathophysiology and agents targeting these pathways could be a potential therapeutic strategy. Expand
Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy.
TLDR
The evidence of mitochondrial dysfunctions on the relation between both disease and pharmacotherapy and the positive effects of chronic treatment by mood stabilizers on mitochondrial functions is reviewed. Expand
Evaluating the Effect of Coenzyme Q10 Augmentation on Treatment of Bipolar Depression: A Double-Blind Controlled Clinical Trial
TLDR
The present pattern of results suggests that among patients with BPD, compared with placebo, adjuvant CoQ10 probably because of its antioxidant and anti-inflammatory properties can improve symptoms of depression over a period of 8 weeks. Expand
A model of the mitochondrial basis of bipolar disorder
TLDR
The central thesis of this paper is that bipolar disorder is due to a phasic dysregulation of mitochondrial biogenergetics, and the elements responsible for this dysregulation may represent critical treatment targets for mood disorders. Expand
Current understanding of bipolar disorder: Toward integration of biological basis and treatment strategies
  • Tadafumi Kato
  • Psychology, Medicine
  • Psychiatry and clinical neurosciences
  • 2019
TLDR
Biological studies of bipolar disorder initially focused on the mechanism of action for antidepressants and antipsychotic drugs, and the roles of monoamines have been extensively studied, but involvement of intracellular calcium signaling has been supported by genetics and cellular studies. Expand
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
TLDR
Novel targets for major depressive disorder are discussed to describe their potential mechanisms of action, the available clinical evidence for these targets, the limitations of available evidence as well as future research directions. Expand
The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment
TLDR
A focused narrative review of the currently available evidence supporting the involvement of mitochondrial dysfunction in mood disorders, the effects of current therapies on mitochondrial functions, and novel targeted therapies acting on mitochondrial pathways that might be useful for the treatment of mood disorders are provided. Expand
Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology
ABSTRACT Multiple novel biological mechanisms putatively involved in the etiology of bipolar disorders are being explored. These include oxidative stress, altered glutamatergic neurotransmission,Expand
Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications
TLDR
The genetic and physiological components of mitochondria and the evidence for mitochondrial abnormalities in BD are discussed and mitochondria is discussed as a potential target of therapeutic interventions in BD. Expand
Treatment of Mitochondrial Disorders
TLDR
This review focuses on newer drugs and treatment trials in mitochondrial diseases, with a special focus on medications to avoid in treating epilepsy and ICU patient with mitochondrial disease, which has not been included in such a review. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 226 REFERENCES
Defects of Mitochondrial Electron Transport Chain in Bipolar Disorder: Implications for Mood-Stabilizing Treatment
  • Jun-Feng Wang
  • Psychology, Medicine
  • Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2007
TLDR
Converging lines of evidence indicate that defects in the mitochondrial electron transport chain (ETC) are associated with bipolar disorder (BD), and that mood-stabilizing drugs produce neuroprotective effects against oxidative damage, and that the process of oxidative damage could be a significant therapeutic target for the treatment of BD. Expand
Mitochondrially Mediated Plasticity in the Pathophysiology and Treatment of Bipolar Disorder
TLDR
It is proposed that although BPD is not a classic mitochondrial disease, subtle deficits in mitochondrial function likely play an important role in various facets of BPD, and that enhancing mitochondrial function may represent a critical component for the optimal long-term treatment of the disorder. Expand
Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia
TLDR
The role of mitochondria during brain development and the effect of current drugs for mental illness on mitochondrial function are described and the evidence for mitochondrial abnormalities in BPD and SZ is reviewed. Expand
Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?
TLDR
L-carnitine and alpha-lipoic acid are pleiotropic agents capable of offering neuroprotective and possibly cognitive-enhancing effects for neuropsychiatric disorders in which cognitive deficits are an integral feature. Expand
Molecular evidence for mitochondrial dysfunction in bipolar disorder.
TLDR
Findings point toward a widespread dysregulation of mitochondrial energy metabolism and downstream deficits of adenosine triphosphate-dependent processes in bipolar disorder. Expand
N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder—A Double-Blind Randomized Placebo-Controlled Trial
TLDR
NAC appears a safe and effective augmentation strategy for depressive symptoms in bipolar disorder. Expand
Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder
TLDR
It is demonstrated that PE and Etn inhibit mitochondrial respiratory activity in a dose-dependent manner, whereas Cho, GPC, and GPE have no measurable effect on bioenergetic function. Expand
Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research
TLDR
A hypothesis of mitochondrial dysfunction in bipolar disorder that involves impaired oxidative phosphorylation, a resultant shift toward glycolytic energy production, a decrease in total energy production and/or substrate availability, and altered phospholipid metabolism is proposed. Expand
Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy
TLDR
ALCAR treatment improves symptoms, causes peripheral nerve regeneration and is proposed as a pathogenesis-based treatment for DSP. Expand
Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic–depressive illness
TLDR
Results suggest that a reconceptualization about the optimal long-term treatment of recurrent mood disorders is warranted, and chronic lithium treatment of patients with manic-depressive illness increases brain N-acetylaspartate levels, an effect that is localized almost exclusively to gray matter. Expand
...
1
2
3
4
5
...